{"title":"布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病后Venetoclax巩固","authors":"Benjamin Heyman, Michael Choi, Thomas J. Kipps","doi":"10.1002/jha2.70085","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long-term side effects.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation. Patients were administered either single-agent venetoclax or in combination with obinutuzumab.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The best peripheral blood minimal residual disease (MRD) response was undetectable MRD, occurring in 89% of patients. With a median follow-up of 47.4 months, both the median progression-free survival and time-to-next treatment were not reached.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Venetoclax consolidation after BTKi is a feasible treatment strategy for patients with CLL, with encouraging efficacy deserving further study.</p>\n \n <p><b>Clinical Trial Registration</b>: N/A</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 4","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70085","citationCount":"0","resultStr":"{\"title\":\"Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia\",\"authors\":\"Benjamin Heyman, Michael Choi, Thomas J. Kipps\",\"doi\":\"10.1002/jha2.70085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long-term side effects.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation. Patients were administered either single-agent venetoclax or in combination with obinutuzumab.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The best peripheral blood minimal residual disease (MRD) response was undetectable MRD, occurring in 89% of patients. With a median follow-up of 47.4 months, both the median progression-free survival and time-to-next treatment were not reached.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Venetoclax consolidation after BTKi is a feasible treatment strategy for patients with CLL, with encouraging efficacy deserving further study.</p>\\n \\n <p><b>Clinical Trial Registration</b>: N/A</p>\\n </section>\\n </div>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 4\",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70085\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70085\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia
Introduction
Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long-term side effects.
Methods
We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation. Patients were administered either single-agent venetoclax or in combination with obinutuzumab.
Results
The best peripheral blood minimal residual disease (MRD) response was undetectable MRD, occurring in 89% of patients. With a median follow-up of 47.4 months, both the median progression-free survival and time-to-next treatment were not reached.
Conclusion
Venetoclax consolidation after BTKi is a feasible treatment strategy for patients with CLL, with encouraging efficacy deserving further study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
